Mild Cognitive Impairment in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01519271|
Recruitment Status : Completed
First Posted : January 26, 2012
Results First Posted : April 7, 2017
Last Update Posted : April 7, 2017
|Study Design||Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
Mild Cognitive Impairment
Drug: Exelon Patch (rivastigmine transdermal system)
Drug: Placebo Patches
|Recruitment Details||Potential participants were a convenience sample of PD patients primarily from the Parkinson’s Disease and Movement Disorders Center at the University of Pennsylvania. Patients between the ages of 40 and 85 y with idiopathic PD for more than 2 years and reporting cognitive were screened for study participation.|
|Pre-assignment Details||48 participants assessed for eligibility, 28 randomized (17 did not meet inclusion/exclusion criteria and 3 refused to participate after screening)|
The small sample size may have limited our power to detect a treatment effect.
When the study was conducted, the maximum strength of the rivastigmine patch was 9.5 mg/24 h. Since then, a higher dose has been approved by the FDA.